Unnatural Products inks $1.7b cardiovascular disease collab with Novartis
Unnatural Products (UNP) signed a research and licensing collaboration with Novartis targeting cardiovascular therapeutics using UNP's macrocyclic peptide discovery platform. The agreement includes roughly $100 million upfront and pre-IND payments plus up to $1.7 billion in development, regulatory and commercial milestones, with Novartis responsible for IND-enabling studies, clinical development and global commercialization.
Why it mattersNovartis's $1.7B cardiovascular collaboration with Unnatural Products demands shifting R&D and investment toward macrocyclic-peptide platforms.